<DOC>
	<DOC>NCT00303199</DOC>
	<brief_summary>The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma</brief_summary>
	<brief_title>Study of ZIO-101 in Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Subjects with multiple myeloma who have received at least two prior therapies and currently require therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Arsenic</keyword>
	<keyword>Cancer study</keyword>
	<keyword>Failed treatment</keyword>
</DOC>